Diagnosis and treatment of KIT-mutant metastatic melanoma

Journal of Clinical Oncology

Volumn 31, Issue 26, 2013, Pages 3176-3181

  Lyle, Megan ^a   Long, Georgina V ^a,b,c  

^a MELANOMA INSTITUTE AUSTRALIA   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHENCYPRONE; IMATINIB; IPILIMUMAB; MELAN A; NILOTINIB; PROTEIN; PROTEIN HMB45; PROTEIN S 100; UNCLASSIFIED DRUG; HMB-45 PROTEIN, HUMAN; MELANOMA ANTIGEN; MLANA PROTEIN, HUMAN; S100A1 PROTEIN; STEM CELL FACTOR RECEPTOR; TUMOR MARKER;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CARCINOGENESIS; CASE REPORT; GENE MUTATION; GENETIC SCREENING; HEEL; HUMAN; LOCAL EXCISION; LUNG METASTASIS; MALE; MELANOMA CELL; METASTATIC MELANOMA; MIDDLE AGED; MITOSIS RATE; ONCOGENE C KIT; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; SANGER SEQUENCING; SENTINEL LYMPH NODE BIOPSY; ULCER; WIDE EXCISION; GENETICS; LEG; LUNG NEOPLASMS; MELANOMA; METABOLISM; MUTATION; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROGNOSIS; SKIN NEOPLASMS;

HUMANS; LEG; LUNG NEOPLASMS; MALE; MART-1 ANTIGEN; MELANOMA; MELANOMA-SPECIFIC ANTIGENS; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT; S100 PROTEINS; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84891550192     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.50.4662     Document Type: Article

References (48)

1. Curtin JA, Busam K, Pinkel D, et al: Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 24:4340-4346, 2006
2. Beadling C, Jacobson-Dunlop E, Hodi FS, et al: KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res 14:6821-6828, 2008
3. Handolias D, Salemi R, Murray W, et al: Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure. Pigment Cell Melanoma Res 23:210-215, 2010
4. Kong Y, Si L, Zhu Y, et al: Large-scale analysis of KIT aberrations in Chinese patients with melanoma. Clin Cancer Res 17:1684-1691, 2011
5. Carvajal RD, Antonescu CR, Wolchock JD, et al: KIT as a therapeutic target in metastatic melanoma. JAMA 305:2327, 2011
6. Hodi FS, Corless C, Giobbie-Hurder A, et al: Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun damaged skin. J Clin Oncol 31:3182-3190, 2013
7. Postow MA, Carvajal RD: Therapeutic implications of KIT in melanoma. Cancer J 18:137-141, 2012
8. Hodis E, Watson IR, Kryukov GV, et al: A landscape of driver mutations in melanoma. Cell 150:251-263, 2012
9. Long GV, Menzies AM, Nagrial AM, et al: Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 29:1239-1246, 2011
10. Lee JH, Choi JW, Kim YS: Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: A meta-analysis. Br J Dermatol 164:776-784, 2011
11. Jakob JA, Bassett RL Jr, Ng CS, et al: NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 118:4014-4023, 2011
12. Devitt B, Liu W, Salemi R, et al: Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. Pigment Cell Melanoma Res 24:666-672, 2011
13. Van Raamsdonk CD, Bezrookove V, Green G, et al: Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 457:599-602, 2008
14. Van Raamsdonk CD, Griewank KG, Crosby MB, et al: Mutations in GNA11in uveal melanoma. N Engl J Med 363:2191-2199, 2010
15. COSMIC: Catalogue of somatic mutations in cancer database. http://www.sanger.ac.uk/genetics/ CGP/cosmic
16. Grichnik, J: Kit and melanocyte migration. J Invest Dermatol 126:945-947, 2006
17. Landi MT, Bauer J, Pfeiffer RM, et al: MC1R germline variants confer risk for BRAF-mutant melanoma. Science 313:521-522, 2006
18. Woodman SE, Lazar AJ, Aldape KD, et al: New strategies in melanoma: Molecular testing in advanced disease. Clinical Cancer Res 18:1195-1200, 2012
19. Torres-Cabala CA, Wang WL, Trent J, et al: Correlation between KIT expression and KIT mutation in melanoma: A study of 173 cases with emphasis on the acral-lentiginous/mucosal type. Mod Pathol 22:1446-1456, 2009
20. Heinrich MC, Griffith DJ, Druker BJ, et al: Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96:925-932, 2000
21. Kim KB, Eton O, Davis DW, et al: Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer 99:734-740, 2008
22. Ugurel S, Hildenbrand R, Zimpfer A, et al: Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer 92:1398-1405, 2005
23. Wyman K, Atkins MB, Prieto V, et al: Multicenter phase II trial of high-dose imatinib mesylate in metastatic melanoma. Cancer 106:2005-2011, 2006
24. Handolias D, Hamilton AL, Salemi R, et al: Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT. Br J Cancer 102:1219-1223, 2010
25. Hodi FS, Friedlander P, Corless CL, et al: Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol 26:2046-2051, 2008
26. Quintaś-Cardama A, Lazar AJ, Woodman SE, et al: Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib. Nat Clin Prac Oncol 5:737-740, 2008
27. Kalinsky K, Lee SJ, Lawrence DP, et al: A phase II trial of dasatinib in patients with unresectable locally advanced or stage IV mucosal, acral, and solar melanomas: An Eastern Cooperative Oncology Group study (E2607). J Clin Oncol 30:545s, 2012 (suppl; abstr 8522)
28. Woodman SE, Trent JC, Stemke-Hale K, et al: Activity of dasatinib against L576P KIT mutant melanoma: Molecular, cellular, and clinical correlates. Mol Cancer Ther 8:2079-2085, 2009
29. Antonescu CR, Busam KJ, Francone TD, et al: L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int J Cancer 121:257-264, 2007
30. Minor DR, Kashani-Sabet M, Garrido M, et al: Sunitinib therapy for melanoma patients with KIT mutations. Clin Cancer Res 18:1457-1463, 2012
31. Guo J, Si L, Kong Y, et al: Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-KIT mutation or amplification J Clin Oncol 29:2904-2909, 2011
32. Antonescu CR, Besmer P, Guo T, et al: Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 11:4182-4190, 2005
33. Prenen H, Cools J, Mentens N, et al: Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clinical Cancer Res 12:2622-2627, 2006
34. Demetri GD, van Oosterom AT, Garrett CR, et al: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 368:1329-1338, 2006
35. Todd JR, Becker TM, Kefford RF, et al: Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells. Pigment Cell Melanoma Res 26:518-526, 2013
36. Robert C, Thomas L, Bondarenko I, et al: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364: 2517-2526, 2011
37. Hodi FS, O'Day SJ, McDermott DF, et al: Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. N Engl J Med 363:711-723, 2010
38. Topalian SL, Hodi FS, Brahmer JR, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443-2454, 2012
39. Brahmer JR, Tykodi SS, Chow LQ, et al: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455-2465, 2012
40. Lawrence D, McDermott DF, Hamid O, et al: Ipilimumab (Ipi) expanded access program (EAP) for patients (pts) with stage III/IV melanoma: Safety data by subgroups. Ann Oncol 23:368, (abstr)
41. Postow MA, Carvajal, R: The efficacy of ipilimumab for patients with mucosal melanoma. Pigment Cell Melanoma Res 25:880, 2012 (abstr)
42. Shaw H, Larkin J, Corrie P, et al: Ipilimumab for advanced melanoma in an expanded access programme (EAP): Ocular, mucosal and acral subtype UK experience. Ann Oncol 23:374, 2012 (abstr)
43. Del Vecchio M, Simeone E, Chiarion Seleni V: Efficacy and safety of ipilimumab in patients with pretreated, mucosal melanoma: Experience from italian clinics participating in the European Expanded Access Programme (EAP). Ann Oncol 23:368, 2012 (abstr)
44. Omholt K, Platz A, Kanter L, et al: NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res 9:6483-6488, 2003
45. Colombino M, Capone M, Lissia A, et al: BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol 30:2522-2529, 2012
46. Dutton-Regester K, Kakavand H, Aoude,L, et al: Melanomas of unknown primary have a mutation profile consistent with cutaneous sun exposed melanoma. Pigment Cell Melanoma Res 25:852, 2012 (abstr)
47. Sequenom: Genetic analysis. http://www.sequenom.com/genetic-analysis
48. Coit DG, Andtbacka R, Anker CJ, et al: Melanoma, version 2.2013: Featured updates to the NCCN guidelines. J Natl Compr Canc Netw 11:395-407, 2013